Trump’s Executive Order on Drug Tariffs
President Donald Trump recently announced a new executive order aimed at implementing tariffs on branded medications, with the intention of reducing the United States’ reliance on drug imports.
In his statement, the president expressed that these tariffs, which will reach as high as 100%, are necessary for national security reasons. However, the order does make exceptions for certain types of medications, particularly generics and orphan drugs.
Industry groups representing pharmaceutical companies have not taken kindly to this move, criticizing it while also defending the imports affected by these tariffs.
In the executive order, Trump stated, “It is necessary and appropriate to impose a 100% ad valorem tax on the import of patented medicines and related pharmaceutical raw materials.” Meanwhile, a significantly lower 15% tariff will be levied on medicines coming from the European Union, Japan, South Korea, Switzerland, and Liechtenstein.
Medicines imported from the UK will face additional charges, although the exact amount will be determined by a framework established in a previous agreement between the U.S. and the UK.
Robert F. Kennedy Jr., Secretary of Health and Human Services, commented, “President Trump’s agreement with the United Kingdom is a significant step towards dismantling a system that forces Americans to pay more than others.” Yet, questions linger about the actual impact of these tariffs on consumers.
Pharmaceutical industry leaders, like Stephen J. Uble, Chairman and CEO of PhRMA, voiced strong objections, stating, “These tariffs raise costs and could threaten billions in U.S. investments made last year.” He stressed that a large portion of medicines utilized in the U.S. are produced domestically, suggesting that innovation is being stifled by increased costs.
As a side note, in February, the Supreme Court had previously invalidated similar tariffs put forth by the president, citing the International Emergency Economic Powers Act in their 6-3 ruling penned by Chief Justice John Roberts.
